Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/21/2024 | Outperform → Mkt Perform | William Blair | |
11/8/2024 | $13.00 | Overweight | Stephens |
8/8/2024 | $10.00 | Buy | Stifel |
5/7/2024 | $10.00 | Buy | Jefferies |
2/9/2024 | $8.00 | Buy | BTIG Research |
1/23/2024 | $12.00 | Outperform | Leerink Partners |
9/5/2023 | $7.00 | Outperform | RBC Capital Mkts |
11/2/2021 | $16.00 | Neutral | B of A Securities |
- Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, formerly PYX-201), driving anti-tumor activity via direct tumor killing, bystander effect and immunogenic cell death - On track to report preliminary data from Phase 1 monotherapy expansion cohorts of MICVO for 2L/3L R/M HNSCC patients who have received prior platinum-based chemotherapy and prior PD-(L)1 inhibitor therapy in second half of 2025, and 2L/3L R/M HNSCC patients who have received prior EGFRi and PD-1 inhibitor therapy in first half of 2026 - On track to report preliminary data from Phase 1 trial of MICVO in combination with pembrolizumab targeting mul
BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in fireside chats and be available for one-on-one meetings with investors at the following two upcoming investor conferences. 2025 RBC Capital Markets Global Healthcare Conference in New York, NY on Wednesday, May 21 at 2:05 p.m. ETJefferies Global Healthcare Conference in New York, NY on Thursday, June 5 at 4:55 p.m. ET A live webcast and replay of the fireside chats will be available on th
Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders Mouse analog of MICVO in a syngeneic model indicated strong activity of the cytotoxic Auristatin0101 payload and potential for MICVO monotherapy to drive immunogenic cell death, a key hypothesis for MICVO's mechanism Combination of a mouse analog of MICVO and anti-PD-1 therapy in a syngeneic model resulted in enhanced tumor clearance and longer immunological memory compared to either treatment alone Totality of pre-clinical data presented at AACR 2025 strongly support MICVO's uniqu
William Blair downgraded Pyxis Oncology from Outperform to Mkt Perform
Stephens initiated coverage of Pyxis Oncology with a rating of Overweight and set a new price target of $13.00
Stifel initiated coverage of Pyxis Oncology with a rating of Buy and set a new price target of $10.00
8-K - Pyxis Oncology, Inc. (0001782223) (Filer)
10-Q - Pyxis Oncology, Inc. (0001782223) (Filer)
8-K - Pyxis Oncology, Inc. (0001782223) (Filer)